Rzeszow

• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting
  2025-523803-31-00 4 2026-04-16 Advanced non-small cell lung cancer (NSCLC)
• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 Hereditary Angioedema
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting
  2024-520098-12-00 4 2026-02-16 Cutaneous Lupus Erythematosus
• Zasocitinib in Nonsegmental Vitiligo Recruiting
  2025-522309-40-00 4 2026-02-11 Non-segmental vitiligo
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting
  2024-520337-80-00 5 2026-01-07 Palmoplantar Pustulosis
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 5 2025-11-13 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 5 2025-10-15 Ulcerative Colitis or Crohn’s Disease
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Co … Recruiting
  2024-520201-39-00 4 2025-08-28 Moderately to Severely Active Ulcerative Colitis
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 5 2025-06-15 Ulcerative colitis
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• A study to evaluate the safety, tolerability, and pharmacokinetics of VABOMERE (meropenem-vaborbactam) in children with complicated urinary … Recruiting
  2024-516360-29-00 4 2025-04-25 Complicated Urinary Tract Infection (cUTI), Acute Pyelonephritis (AP)
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting
  2023-503188-40-00 5 2025-01-06 Active Ulcerative Colitis or Crohn’s Disease
• Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting
  2023-505283-11-00 6 2024-12-10 Relapsing forms of Multiple Sclerosis (RMS)
• A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag … Recruiting
  2023-503630-44-00 10 2024-11-20 Treatment of moderate-to-severe Atopic dermatitis
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting
  2023-504358-36-00 5 2024-10-17 multiple sclerosis
• Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting
  2023-508304-38-00 4 2024-09-10 Ulcerative Colitis (UC)

Showing 25–48 of 324 trials